Biologics/Immunotherapy News

LOUISVILLE, Ky. — Of approved biologics for severe, allergic asthma, tezepelumab was the only one to consistently reduce the annualized exacerbation rate across patient subgroups, according to a literature review.

LOUISVILLE, Ky. — Patients with chronic spontaneous urticaria experienced improvements with dupilumab, according to a study presented at the American College of Asthma & Immunology Annual Scientific Meeting.

LOUISVILLE, Ky. — Epicutaneous immunotherapy conferred a significant response after 12 months among children aged 1 to 3 years with peanut allergy, according to results of the phase 3 randomized, double-blind EPITOPE study.

LOUISVILLE, Ky. — Allergen-specific immunotherapy showed efficacy among patients with atopic and contact dermatitis overlap syndrome, according to results of a pilot study.

LOUISVILLE, Ky. — Researchers showed with moderate certainty that topical calcineurin inhibitors did not increase cancer risk when used as a treatment for atopic dermatitis among infants, children and adults, according to study results.

LOUISVILLE, Ky. — “OIT is a marathon and not a sprint,” Aikaterini (Katherine) Anagnostou, MD, PhD, FACAAI, said during a lecture. “The families need to know that, and the kids need to know too.”

After working with the American College of Asthma, Allergy & Immunology for 3 decades, Kathleen May, MD, FACAAI, is excited to be taking its reins as president during its 2022 Annual Scientific Meeting, Nov. 10 to 14, in Louisville, Ky.

Upadacitinib was well tolerated with no new important safety risks among patients with moderate to severe atopic dermatitis treated for approximately 1 year, according to a study published in The Journal of Allergy & Clinical Immunology.

NASHVILLE, Tenn. — There are no simple solutions in asthma treatment, as evidenced by a debate that covered airway remodeling and the use of oscillometry among other topics at the CHEST Annual Meeting.

A 200 mg dose of abrocitinib met stringent efficacy endpoints among substantial portions of patients with moderate to severe atopic dermatitis, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.